Article Text

PDF
CP-075 Prognostic factors in patients with recurrent epithelial ovarian cancer
  1. A Rodriguez Palomo1,
  2. FJ Alvarez Manceñido1,
  3. I Zapico García1,
  4. L Sanchez Lorenzo2,
  5. P Pena Villanueva3,
  6. A Carmona Bayonas4,
  7. M Sanchez Canovas4,
  8. L Faez2,
  9. MP Solis2,
  10. P Jimenez Fonseca2
  1. 1Hospital Universitario Central de Asturias, Pharmacy, Oviedo, Spain
  2. 2Hospital Universitario Central de Asturias, Oncology, Oviedo, Spain
  3. 3Hospital Universitario de Cabueñes, Pharmacy, Gijon, Spain
  4. 4Hospital Universitario Morales Meseguer, Oncology, Murcia, Spain

Abstract

Background Pegylated liposomal doxorubicin (PLD) is indicated in ovarian cancer patients who have failed firstline platinum based chemotherapy. Currently, there are no clinical or biomolecular factors that can predict the benefit of PLD in this population.

Purpose To identify clinical predictors of overall survival (OS) in patients with recurrent ovarian cancer treated with PLD.

Material and methods 9 baseline variables were evaluated to assess its prognostic ability in 143 patients treated with PLD from January 2008 to January 2014. The analysed variables were: Eastern Cooperative Group Performance Status (ECOG-PS), age, histopathology, treatment line, platinum sensitivity (progression free interval(PFI)) and chemotherapy schedule (monotherapy vs polychemotherapy). Cox regression models were used to calculate the log hazard ratio, and the most parsimonious model was selected according to the Akaike information criteria.

Results The prognostic index includes four variables associated with OS: ECOG-PS (>70), age (≤70 years), platinum highly sensitive (PFI ≥12 months after completion of frontline platinum based chemotherapy) and use of combination chemotherapy (PLD and carboplatinum/gemcitabine/trabectidin were assigned 2 points and intermediately sensitive (PFI 6–12 months) was assigned 1 point). The global median progression free survival for all patients was 5.9 months (95% CI 4.0–7.3) and median OS was 18.8 months (95% CI 15.2–23.3). The score had the potential to delineate five prognostic groups whose results are shown in the table.

View this table:

Conclusion Young age (<70 years), good performance status, platinum sensitivity and PLD based polychemotherapy proved to be predictive and prognostic factors. Therefore, these factors should be considered when making decisions about the approach to these patients. Nevertheless, this preliminary evidence must be validated in a prospective clinical trial.

No conflict of interest

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.